Lupin has informed that it has enclosed a Press Release on 30th April 2020 as regards receipt of Establishment Inspection Report from the US FDA for the Company’s Pithampur Unit-1, India facility. Inspection for the said facility was conducted by the US FDA between February 3, 2020 and February 11, 2020 and concluded with two observations.
The above information is a part of company’s filings submitted to BSE.